Fluo-4 Calcium-Transient Imaging of Drug-Modulated Excitation-Contraction Coupling in hiPSC-Cardiomyocytes

Each pharmacological condition is tested on ≥3 independent cardiomyocyte preparations (separate differentiations/plates), imaging ≥8 fields and ≥30 single cells/regions of interest per condition. A within-cell paired design is used where feasible (baseline → drug on the same field) to control for cell-to-cell variability. Concentration-response is run for isoproterenol (1 nM-1 µM) and nifedipine (1 nM-1 µM). Caffeine (10 mM) is applied as a single rapid bolus for SR-load assessment. Recordings are 20-30 s at 50-100 frames/s. hiPSC-CMs are used at day 25-40 for stable transients.

BSL-2 for human-derived cells. Nifedipine and caffeine stocks are biologically active — handle with gloves; nifedipine is light-sensitive and must be protected from light. Fluo-4 AM and Pluronic stocks are in DMSO (skin-penetration enhancer) — avoid skin contact. PPE: lab coat, nitrile gloves, safety glasses. Imaging buffer waste with drugs is collected as mixed chemical/biohazard waste; biological waste bleached to 10% final. The microscope laser/LED illumination is contained — follow instrument laser-safety guidance.

Vehicle/time control: DMSO/Tyrode's additions matched in volume and timing reveal photobleaching and time-dependent rundown, which are subtracted. Positive functional control: isoproterenol must increase amplitude, accelerate decay, and raise rate; caffeine must evoke a large single transient (confirms SR loading). Negative/inhibitory control: nifedipine must reduce transient amplitude, confirming LTCC dependence. Dye-loading control: an unloaded field confirms autofluorescence is negligible; a non-beating (e.g., nifedipine-arrested) field anchors baseline F0. Background ROI in a cell-free region corrects illumination drift.

Healthy hiPSC-CMs show rhythmic Ca2+ transients of ΔF/F0 ≈ 0.5-3, time-to-peak ~100-300 ms, decay tau ~200-600 ms, at 0.5-1.5 Hz. Isoproterenol typically increases amplitude 20-80%, shortens tau, and raises rate. Nifedipine reduces amplitude dose-dependently toward quiescence. A 10 mM caffeine bolus elicits a single transient larger than the steady-state transient, indicating intact SR Ca2+ stores. Vehicle drift in amplitude should be <10% over the recording.

• hiPSC-CMs replated as low-density single cells / small clusters on fibronectin-coated glass-bottom dishes or 96-well imaging plates
• Fluo-4 AM (Thermo F14201), 1 mM stock in DMSO; working 2-5 µM
• Pluronic F-127 (20% in DMSO), to 0.02% final, to aid dye solubilization
• Tyrode's solution (mM): 140 NaCl, 5.4 KCl, 1 MgCl2, 1.8 CaCl2, 10 HEPES, 10 glucose, pH 7.4 (imaging buffer)
• Probenecid (optional, 1-2 mM) to reduce dye extrusion
• Isoproterenol HCl, 1 mM stock; working 1 nM-1 µM
• Nifedipine, 10 mM stock in DMSO (light-protected); working 1 nM-1 µM
• Caffeine, 0.5 M stock in Tyrode's; working 10 mM bolus
• DMSO vehicle control (<0.1% final)

To quantify intracellular calcium handling in spontaneously beating hiPSC-derived cardiomyocytes using the cell-permeant indicator Fluo-4 AM and high-speed fluorescence imaging, extracting transient amplitude (ΔF/F0), time-to-peak, decay time constant (tau), and beat frequency, and to validate the readout pharmacologically against β-adrenergic stimulation, L-type Ca2+ channel block, and SR Ca2+-store assessment by caffeine.

1. Replate hiPSC-CMs as single cells/small clusters on fibronectin-coated glass-bottom dishes; culture 3-7 days to re-attach and resume beating.
2. Prepare loading solution: 5 µM Fluo-4 AM + 0.02% Pluronic F-127 (± 1 mM probenecid) in Tyrode's solution.
3. Load cells 30 min at 37°C protected from light; then wash 2x with dye-free Tyrode's and de-esterify 15-20 min at 37°C.
4. Mount on a temperature-controlled (37°C) microscope stage; allow 5 min equilibration.
5. Acquire 20-30 s baseline at 488 nm excitation / ~515 nm emission, 50-100 fps, minimal exposure to limit photobleaching.
6. Apply drug by gentle bath exchange (replace ≤10% volume with concentrated stock); equilibrate 3-5 min; re-record the same field.
7. For SR load, rapidly apply 10 mM caffeine while recording continuously to capture the single evoked transient.
8. Acquire matched vehicle-control fields with identical timing/volume additions; correct for photobleaching with a background ROI.

Independent variables: drug identity and concentration; caffeine bolus. Dependent variables: ΔF/F0 amplitude, time-to-peak, decay tau, beat frequency, and (caffeine) SR-release amplitude. Controlled variables: temperature (37°C), Tyrode's [Ca2+] (1.8 mM) and pH (7.4), dye concentration/loading time, frame rate/exposure, illumination intensity, cell age (day 25-40), and field selection criteria (only clearly beating, single-layer cells). Photobleaching is controlled by minimizing light dose and background subtraction.

β-adrenergic stimulation (isoproterenol) will increase Ca2+ transient amplitude, accelerate decay (lower tau, reflecting PKA-enhanced SERCA/phospholamban activity), and increase beat rate; L-type Ca2+ channel blockade (nifedipine) will reduce transient amplitude and slow/abolish beating; and a rapid caffeine application will trigger a single large SR Ca2+-release transient, allowing estimation of SR Ca2+ load. These responses confirm functional, SERCA- and LTCC-dependent excitation-contraction coupling.

Time-series fluorescence is extracted per ROI in ImageJ/Fiji or Python; F0 is the diastolic baseline. ΔF/F0 = (F-F0)/F0. Each transient is fit per beat: amplitude (peak ΔF/F0), time-to-peak, and a single-exponential decay fit for tau. Beat frequency is computed from peak-to-peak intervals. Values are averaged per cell, then per preparation. Photobleaching is corrected by dividing by a background-ROI trend or fitting/removing a slow exponential. Specialized packages (e.g., CalTrack, or vendor cardiac-Ca modules) automate transient detection.

1. Weak/no Fluo-4 signal: poor loading or dye extrusion — increase dye to 5 µM, add 0.02% Pluronic and 1-2 mM probenecid, and confirm complete de-esterification. 2. Rapid signal rundown/photobleaching: light dose too high — reduce LED intensity/exposure, lower frame rate, and apply background-trend correction. 3. No isoproterenol response: cells too immature or β-receptors desensitized — use day-30+ cells and fresh isoproterenol (oxidizes quickly). 4. No caffeine-evoked transient: empty SR or arrested cells — ensure cells were beating and SR-loaded before caffeine; verify caffeine stock. 5. Motion artifacts during contraction: ROI drifts off cell — use motion-correction/registration or analyze low-motion regions, or add a mechanical uncoupler (e.g., blebbistatin) if only Ca2+ is of interest.

Paired baseline-vs-drug comparisons within the same field use a paired t-test or Wilcoxon signed-rank (per normality, Shapiro-Wilk), with cells nested within preparations analyzed by a linear mixed-effects model (preparation as random effect) to avoid pseudoreplication. Concentration-response amplitude data are fit with a Hill equation; EC50/IC50 CIs from the fit. Multiple parameters (amplitude, tau, rate) across conditions use one-way ANOVA with Bonferroni/Holm correction, α=0.05, n≥3 preparations and ≥30 cells/condition.